
Thin at what cost? The mental toll of the weight-loss race
Thanks to an overload of celebrity endorsements and viral TikTok trends, weight loss is no longer just a personal health goal. It has become a high-pressure, high-stakes race. However, as the kilos drop, another kind of weight creeps in: the silent, growing burden on our mental health.It is indeed a race — but one that needs reimagining.The pressure to be 'thin' or 'fit' has never been higher. However, the stress, the obsession, and the emotional fragility it produces often go unspoken. As India enters the injectable era of weight loss, experts warn: obesity must not be treated in isolation. The body and mind must heal together.advertisementWeight-Loss Drug Conundrum
So, what's on offer for the body? Quite a lot.Weight-loss injectables (the GLP-1 receptor agonists) have become the pharmaceutical industry's newest repository. Mounjaro (tirzepatide), has already sold over 81,500 units and generated Rs 239 million in revenue, the sales having spiralled by 60% in just one month. Wegovy (semaglutide), after its success in the U.S. and Europe, launched in India recently. The recommended prices for this range from Rs 17,345 to Rs 26,050 per month. There are other GLP-1 analogues too like Ozempic, Zepbound, and Rybelsus which are also a part of India's urban health lexicon. Some of these are legally approved, others are accessed through grey-market channels.Yes, India Needs These DrugsIndia is battling a silent epidemic: obesity. 24% of women and 23% of men aged 15–49 are overweight or obese, according to the NFHS-5 report. Urban obesity is also on an uptick. Nearly half of Indian women aged 35–49 fall into the overweight or obese category, with central obesity being especially prevalent. advertisementAccording to the 2023–24 Economic Survey, obesity in India has tripled over the past decade, amongst middle-aged adults. This also explains the rush toward weight-loss medications.What About Our Minds?While we obsess over physical transformation, mental health is often the silent casualty. 1 in 7 Indians live with some form of mental illness, according to the National Mental Health Survey, and the treatment gap is even more alarming: over 70% of those with depression or anxiety never receive care.There is growing evidence of a bidirectional link between obesity and mental health. Over 80% of individuals with psychiatric illnesses are overweight or obese. Similarly, many obese individuals experience anxiety, depression, and body image dissatisfaction.The 'Stress' Of The SolutionWhile these drugs may address physical concerns, they often trigger an emotional fallout. The cost is not just financially burdensome, it is psychologically draining too, with some patients reporting visible mood swings, appetite loss, body dysmorphia, and even social withdrawal.Adding to this is the stigma of being on medication for weight loss — a condition still wrongly viewed as a matter of willpower rather than biology!Dr. Anjali Sood, an endocrinologist based in Mumbai, feels we're fixing the body, but forgetting the brain. She says: 'GLP-1 receptor agonists are revolutionary. They work in the brain's hunger centres—but that also means we can't ignore their psychological effects. Patients often feel emotionally fragile, especially when physical results slow down.' advertisementShe warns against the 'magic fix' narrative: 'Weight loss is more than a metabolic issue. It's deeply tied to identity, trauma, and mental health. The syringe may help the body—but not always the mind.'A clinical psychologist in Noida, Dr Saurabh Moitra, agrees. 'Many of my patients, especially young women, are under pressure to deliver 'before-and-after' results." When weight doesn't drop quickly, shame and guilt set in. Some develop disordered eating or social anxiety.'He adds: 'Thin doesn't mean happy (always). And our current health ecosystem doesn't prepare patients for that emotional contradiction.'India urgently needs protocols that integrate mental health support with weight-loss treatment. Countries like Denmark and the U.S. are already considering mandatory psychological screenings before prescribing GLP-1s. Experts recommend a collaborative model of care with endocrinologists, psychologists, nutritionists, and general practitioners working together.We can't afford to fight obesity with blinkers on. Without a mental health infrastructure, we're just moving the problem from body to mind.- Ends
advertisement

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Indian Express
42 minutes ago
- Indian Express
Atal Institute of Medical Super Specialties to be Himachal's first to perform robotic surgery
The Atal Institute of Medical Super Specialities (AIMSS) at Chamiyana in Shimla is set to become the first medical institute in Himachal Pradesh to introduce surgeries using cutting-edge robotic technology. A state-of-the-art surgical robot — procured at a cost of Rs 28 crore on the lines of AIIMS Delhi — has already arrived at the institute. The installation process is expected to be completed by July, following which robotic-assisted surgeries will commence. Dr Brij Lal, principal, AIMSS Chamiyana, said that robotic surgery will offer significant benefits to both patients and doctors. 'Robotic procedures require only small incisions, resulting in minimal blood loss, reduced need for transfusions, and faster recovery for patients. They experience less pain and are discharged sooner,' he said. Doctors too will gain from the technology, as robotic systems enhance surgical precision and control. 'Surgeons experience less fatigue, even during prolonged operations, enabling them to perform more procedures efficiently. The technology provides a clear, magnified 3D view of narrow and complex areas within the body, significantly reducing the risk of errors,' Lal added. Meanwhile, a government spokesperson said in a bid to further strengthen healthcare infrastructure in Himachal Pradesh, Chief Minister Sukhvinder Singh Sukhu is set to visit Dr Rajendra Prasad Government Medical College (RPGMC), Tanda. As part of the visit, a detailed presentation will be made on the ongoing and proposed improvements in medical services and infrastructure at the institute. 'The CM will also engage in an interactive session with the faculty members to gather feedback and suggestions, focusing on enhancing healthcare delivery at this key medical institution,' the spokesperson added.


India Today
an hour ago
- India Today
Ozempic & Celebs: The Real Stories Behind the Weight Loss
Ozempic & Celebs: The Real Stories Behind the Weight Loss By: Kashmik Singh Chouhan Lately, medicines made for diabetes are being used by many people to lose weight. But do they really work? Are they safe? This story breaks it down in a simple way. New-age medications like Ozempic and Wegovy, originally meant for diabetes, are now being widely used for rapid weight loss. But what's really happening behind the trend? 1. The Buzz Around GLP-1 Drugs Many users report quick fat loss sometimes over 30 pounds. But it often comes with fatigue, nausea, or even depression. Is it worth the hype? 2. Weight Loss vs Wellness These drugs don't magically erase emotional eating or body image issues. Medical experts stress: long-term change still needs mindset work and lifestyle effort. 3. More Than Just a Shot People are increasingly turning to weight-loss drugs under the pressure of looking a certain way especially in social media or public life. It's reshaping beauty standards, for better or worse. 4. Social Pressure & Perception Some say the medication gave them physical transformation but made them feel disconnected or less confident. Inner confidence doesn't always come with outer change. 5. The Confidence Trap Doctors caution that once people stop the meds, weight often returns. These drugs can manage symptoms—not cure root causes of weight gain. 6. Temporary Wins, Lasting Questions Users who stopped the drug say it wasn't sustainable: nausea, weakness, or mental fog led them to step away and opt for natural, slower transformations. 7. Why Some Quit There's growing stigma about 'who's on Ozempic'—especially in industries obsessed with appearance. Many feel judged whether they use it or not. 8. Stigma and Speculation From potential nutrient loss to muscle wasting, risks are real. Medical guidance, regular checkups, and mental health support are essential. 9. Balancing Risk and Reality Weight loss drugs can be tools not solutions. Transparency, medical advice, and realistic goals make the journey healthier than shortcuts alone. 10. The Final Word


Time of India
2 hours ago
- Time of India
Tata Memorial Centre to provide affordable high-dose MIBG therapy for neuroblastoma
Mumbai: A high-dose MIBG (metaiodobenzylguanidine) therapy for treating neuroblastoma, a type of cancer mostly found in children, will be provided at an affordable cost of Rs 7-8 lakh at a research body associated with the Tata Memorial Centre ( TMC ). The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), a unit of TMC at Kharghar in Navi Mumbai, treated a 17-year-old with a supra-high dose of 131I-mIBG on May 5. Talking to reporters on Friday, TMC director Dr Sudeep Gupta said the treatment of children with high-risk neuroblastoma, which requires a multi-modality approach including anti-GD2 immunotherapy, costs around Rs 75 lakh and has a long-term cure outcome of 50 per cent. "The anti-GD2 immunotherapy is exceptionally expensive and is not accessible to many patients in India. However, the high-dose 131I-mIBG therapy costing Rs 7-8 lakh is affordable. With 41 'hot beds' medical isolation ward, the largest in the world, the TMC plans to routinely provide this treatment to eligible patients with high-risk neuroblastoma," he said. Even the toilet and wash water from the room are piped to a sealed "delay-decay" tank so the radioactivity can fade before the wastewater is released into the regular sewer system. Live Events This is the first high-dose 131I-mIBG therapy administered in India with a 25-35 per cent long-term cure outcome, where the patient was administered 800 mCI of 131I-mIBG. In India, the standard dose of 131I-mIBG is 5 millicuries per kilogram (maximum 300 mCI). "The previous highest total dose of 131I-mIBG in a single setting in India has been 300 mCI. Specialists from the departments of nuclear medicine, paediatric oncology, haematological oncology (bone marrow transplant) and transfusion medicine were involved in the planning and execution of this complex treatment," Dr Gupta said. For the higher dose, the Atomic Energy Regulatory Board (AERB) gave its approval after the TMC submitted a report from a simulation experiment at the premises, addressing issues such as isolation protocols, radiation safety concerns, dosimetry calculations, patient monitoring and management of emergency crises. He said this treatment requires coordination of doctors, physicists, technical staff, nurses and auxiliary staff from the departments of nuclear medicine, paediatric and haematological oncology (bone marrow transplant unit) and transfusion medicine, and the Board of Radiation and Isotope Technology (BRIT). In India, 1,500 children are detected with neuroblastoma annually, Dr Gupta added. PTI